

Can We Predict the Fate of Vulnerable Plaque: Progression or Regression?

Michael Joner, MD
CVPath Institute,
Gaithersburg, MD, USA

Non-Progressive and Progressive Coronary Plaques

non-progressive

progressive











adaptive intimal thickening

Intimal xanthoma

pathologic intimal thickening

fibroatheroma

thin-cap fibroatheroma



lipid pool

necrotic core

early → late necrosis




Histomorphometric Analysis of Plaque Component

PIT (no Macs)

PIT (+ Macs)

Early FA




Late FA



Macrophage (KP-1.CD68)




In-Situ End Labeling (DNA fragmentation, apoptosis)




Plaque Progression: From PIT (LP) to Fibroatheroma (NC)



*PIT w/o
M ϕ*







OCT







Histology







*PIT with
M ϕ*



Early FA




Late FA



FA=fibroatheroma; LP=lipid pool; NC=necrotic core; PIT=pathologic intimal thickening









Causes of Coronary Thrombosis

Rupture
60 to 75%




Erosion 30-35%

Calcified nodule (2 to 7%)




Can we better characterize the differences between these three types of plaques?





Plaque Rupture




Thin cap fibroatheroma





Fibroatheroma -SP



Plaque Rupture and TCFA with Varying Luminal Stenosis










*Narula J, Nakano M, et al.
J Am Coll Cardiol 2013;61:1041-51.*




Gross and Light Microscopic Features of Plaque Rupture

60% of Thrombi in Sudden Coronary Death occur form Plaque Rupture





Do TCFA (vulnerable plaques) Continue to Progress and Rupture?



Thin cap fibroatheroma





- Necrotic core ($21.6 \pm 23.7\%$)
- Thin fibrous cap ($< 65 \mu\text{m}$)
- Cap infiltrated by macrophages and lymphocytes
- Cap composition – type 1 collagen with few or absent smooth muscle cells




Plaque Rupture

- Discontinuous fibrous cap ($23 \pm 19 \mu\text{m}$)
- Underlying necrotic core ($29.0 \pm 19.0\%$)
- Luminal thrombus



Remodeling in Varying Coronary Lesion Morphologies



Medial SMC apoptosis




Relationship of Fibrous Cap Thickness to Macrophage Infiltration



Independent Morphological Predictor of Rupture


50-75% cross-sectional stenosis




	P Value	Odds Ratio	95% CI
Cap thickness	0.005	0.35	0.16 – 0.69
%NC	0.02	2.0	1.1 – 3.7
%Macrophage	0.052	1.8	0.99 – 3.2

Frequency and Location of Unstable Lesions: Thin-cap Atheromas, Acute and Healed Ruptures in the Coronary Circulation



Thin-cap Fibroatheroma



Acute Plaque Rupture




Healed Plaque Rupture




Plaque Rupture with Acute Thrombus


OCT



IVUS




Histology




Healed Plaque Rupture





IVUS



OCT



Histology









Features of ruptured plaques

- Thrombus
 - Large necrotic core (>30% of plaque)
 - Fibrous cap covering the necrotic core
 - thin (thickness usually <65 μm)
 - many macrophages (inflammation)
 - few smooth muscle cells (apoptosis)
 - Expansive remodeling preserving the lumen
 - Neovascularization from vasa vasorum
 - Plaque hemorrhage
 - Adventitial/perivascular inflammation
 - “Spotty” calcification
-

Plaque Erosion: 30-35% of thrombi in SCD

Plaque erosion in a 33 year-old female complaining of chest pain for two-weeks and discharged from the emergency room with a diagnoses of anxiety.






Can plaque erosion be identified by OCT/OFDI?

51F presented
with STEMI

Luminal thrombus without plaque rupture

Sub-occlusive thrombus





Fineschi M, J Cardiovasc Med 2013 [Epub ahead of print]

- ❖ Thrombus may obscure the underlying plaque morphology.
- ❖ Currently, no distinct morphological features of erosion-prone plaques have been identified.

Plaque Erosions in Men and Women Stratified by Age

Men

Women




*P=0.01, †P=0.02, ¥p=0.01, ^P=0.03


All P > 0.05

Calcified Nodule

A






B




Frequency 2-7% of SCD, Older individuals, usually Men, equally common in tortuous right and left coronary arteries

Nodular Calcification and Calcified Nodule on OCT/OFDI



Calcified Nodule as Detected by OCT







However, the precursor lesions of calcified nodule remain to be clarified.

Plaque Fissure

Plaque Rupture

Healed Plaque Rupture

Fibrocalcific Plaque






Calcified Plate Fragmentation

Nodular Calcification

Calcified Nodule with luminal thrombus

Calcified plate



Calcified Plate fragmentation from artery tortuosity and beating heart

Nodules of calcium Destroying the media



Medial destruction

Luminal thrombus surrounded by Fibrin and platelet


Macrophage Diversity around
Angiogenesis, Plaque Hemorrhage and
Iron deposits - Markers of Plaque
Progression ?

Intraplaque Hemorrhage

▲ Angiogenesis




Frequency of Plaque Hemorrhage




Morphometric Analysis of Hemorrhagic Events in Human

Hemorrhagic
Pericarditis









Vulnerable Plaque



Plaque Type	GpA Score	Iron	Necrotic Core (mm ²)	MΦ (mm ²)
PIT <i>no core</i> (n=129)	0.09 ± 0.04	0.07 ± 0.05	0.0	0.002 ± 0.001
FA <i>early core</i> (n=79)	0.23 ± 0.07	0.17 ± 0.08	0.06 ± 0.02	0.018 ± 0.004
FA <i>late core</i> (n=105)	*0.94 ± 0.11	*0.41 ± 0.09	*0.84 ± 0.08	*0.059 ± 0.007
TCFA (n=52)	*1.60 ± 0.20	*1.24 ± 0.24	*1.95 ± 0.30	*0.142 ± 0.016




Values are reported as the means ± SE, *p<0.001 versus early core. The number in parenthesis represent the number of lesions examined; the total number= 365. MΦ = macrophages

TCFA with Intraplaque Hemorrhage




Distribution of Macrophage Sub-type

Human coronary plaque



Macrophage Diversity



Summary:

Progression of Vulnerable Plaque

- Vulnerable plaques (TCFA) is a likely precursor lesions of rupture. Macrophage infiltration plays an important role in modification of plaque vulnerability.
- Plaque erosion occurs principally in younger individuals, especially women with a smoking history. The underlying plaque consists of PIT or fibroatheroma; however, distinct morphological features of erosion-prone plaques have not been identified.
- Calcified nodules are another substrate for thrombosis, especially in elderly male individuals with high plaque burden, tortuous arteries, diabetes or metabolic syndrome, hypertension, and smoking.
- Intraplaque hemorrhage from “leaky” vasa vasorum is an important contributor to necrotic core expansion and potential lesion instability.
- Macrophage subtypes may help us better understand the role of plaque hemorrhage and plaque stabilization vs. plaque rupture.
- Novel imaging technologies have progressed to detect VP but limitations remain due to lack of understanding of VP progression

Acknowledgments

Funding

CVPath Institute Inc.

CVPath Institute

Kazuyuki Yahagi, MD

Fumiyuki Otsuka, MD, PhD

Kenichi Sakakura, MD

Elena Ladich, MD

Robert Kutz, MS

Ed Acampado, DVM

Youhui Liang, MD

Abebe Atiso, HT

Jinky Beyer

Giselle Magsalin

Hedwig Avallone, HT

Lila Adams, HT

Hengying Ouyang, MD

Frank D Kolodgie, PhD

Renu Virmani, MD

